ICH GCP »8. ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL

August 29, 2013 – 01:54
ICRC-Weyer Contract Research Organization

Document Purpose 8.3.1 Updates of the Investigator's Brochure (IB) To document that the investigator must be informed promptly of the relevant information as it becomes available 8.3.2 Revisions
- Protocol / amendment (s) and CRF
- Informed Consent Form
- Any other written information provided to subjects
- Alerts for subject recruitment (if used) To document revisions of these documents that came into effect during the study 8.3.3 Approval / favorable opinion dated and documented IRB / IEC with regard to:
- Amendment (s) of the Protocol
- A review of:
- Informed consent form
- Any other written information to be provided to subjects
- Alerts for subject recruitment (if used)
- Other documents that have received approval / favorable opinion
- Continuing review of the study (if required) To document that '(the) amendment (s) and / or revisions have been submitted to the IRB / IEC and have received approval / favorable opinion. To identify the version and date of the document (s) (s) 8.3.4 A UTHORIZATION / Approval / Notification of regulatory authorities, if required, to:
- Amendment (s) of the protocol and other documents To document compliance with applicable regulatory requirements 8.3.5 Curriculum Vitae for new (i) the investigator (s) and / or co-investigator (s) See 8.2.10 8.3.6 Updates normal values ​​/ ranges for procedures / medical examinations / instrumental / laboratory included in the protocol To document normal values ​​and ranges that were reviewed during the study (see 8.2.11) 8.3.7 Updates to procedures / medical examinations / instrumental / laboratory:
- Certification or
- Accreditation or
- Quality control and / or external quality assessments or
- Other validation (if required) To document that tests remain adequate throughout the course of the (if required) study (see 8.2.12) 8.3.8 Documentation submission (s) Product (s) in the studio and materials related to the study (See 8.2.15) 8.3.9 Certificate (s) of analysis for new batches of products in study (See 8.2.16) 8.3.10 Reports of monitoring visits To document the visits at the center and the observations dell'addetto monitoring 8.3.11 Other relevant items in addition to the reports of visits
- Letters
- Notes of meetings
- Notes of telephone calls To document any agreements or significant discussions regarding the administrative aspects of the study, protocol violations, the conduct of the study, the reporting of Adverse Events 8.3.12 Informed consent forms signed To document that consent has been obtained in accordance with the Good Clinical Practice and with the protocol and dated prior to the subject's participation in the study. Also to document direct access permission (see 8.2.3) 8.3.13 Original Documents To document the existence of the subject and to validate the integrity of the study data collected. To collect the original documents relating to the study, the clinical treatments and medical history 8.3.14 Cards collecting data (CRF) completed, signed, dated To document that the investigator or an authorized member of his staff, with-(copy) (original) 8.3.15 Documentation of corrections in CRFs To document all changes / additions or corrections made on the CRF after initial data recording 8.3.16 Notification of the investigator to the sponsor of serious adverse events and related reports Notification of the investigator to the sponsor of serious adverse events and related reports in accordance with paragraph 4.11 8.3.17 Notification of the sponsor and / or investigator, where applicable, to the regulatory authorities and the IRB / IEC of adverse drug reactions and other serious or unexpected safety information Notification of the sponsor and / or investigator, where applicable, to regulatory authorities and IRB / IEC adverse drug reactions serious and unexpected in accordance with the points 5.17 and 4.11.1 and other safety information in accordance with section 16.5 .2 8.3.18 Notification of the sponsor to investigators of safety information Notification of the sponsor to investigators of safety information in accordance with section 5.16.2 8.3.19 Interim or annual reports to IRB / IEC and the Authority Interim or annual reports provided to IRB / IEC in accordance with section 4.10 and to the authorities in accordance with section 5.17.3 8.3.20 Register persons valutat To document identification of subjects who entered the pre-selection study List of codes to identify subjects To document that the investigator / institution keeps a confidential list of names of all persons to whom has been assigned a number for the study at enrollment. It allows the investigator / institution to reveal the identity of each subject Register of subjects enrolled To document the enlistment from a chronological point of view, using the numbering given to subjects Quantitative management of (i) product (s) in the studio at the headquarters experimental To document that the product (s) (i) has been used in the study according to the protocol Sheet of signatures To document signatures and initials of all Registration of any samples of organic nature (fluid / tissue) stored To document the place of preservation and identification of samples if the tests are to be repeated

Source: ichgcp.net

The Guilford Press Clinical Handbook of Psychological Disorders, Fourth Edition: A Step-by-Step Treatment Manual (Barlow: Clinical Handbook of Psychological Disorders)
Book (The Guilford Press)

From the actual studies of "placebo" effects

2006-11-13 16:53:32 by read_this_

Hrobjartsson and Götzsche published a study in 2001 and a follow-up study in 2004 questioning the nature of the placebo effect. (Hrobjartsson 2001, Hrobjartsson 2004) They performed two meta-analyses involving 156 clinical trials in which an experimental drug or treatment protocol was compared to a placebo group and an untreated group, and specifically asked whether the placebo group improved compared to the untreated group. Hrobjartsson and Götzsche found that in studies with a binary outcome, meaning patients were classified as improved or not improved, the placebo group had no statistically significant improvement over the no-treatment group

You might also like:

CDISC eSubmissions 2012 Part 1
CDISC eSubmissions 2012 Part 1

Foreign companies stop clinical trials in India after government amends rules ..  — Times of India
Patients who participate in a clinical trial receive greater degree of medical care than they would have under regular treatment because of the high level of investigations and patient management that a clinical study protocol requires,'' Thatte said ..

Wiley Design and Analysis of Clinical Trials: Concepts and Methodologies (Wiley Series in Probability and Statistics)
Book (Wiley)
Academic Press Writing Clinical Research Protocols: Ethical Considerations
Book (Academic Press)
Protocol Protocol - Occu Support Clinical Strength 90 Capsules
Beauty (Protocol)
  • 90 Capsules
  • Serving Size: 3
  • 30 Servings Per Container

Related posts:

  1. Medical studies Austin TX
  2. Medical Study Protocol template
  3. Medical and Research Council
  4. Medical research Pros and Cons
  5. Medical and Research